Risk Matrix for Prediction of Disease Progression in a Referral Cohort of Patients with Crohn's Disease.
暂无分享,去创建一个
M. Papp | P. Lakatos | Z. Shums | G. Norman | N. Sipeki | P. Antal-Szalmás | G. Kovács | P. Golovics | B. Lovász | Eszter Pályu | P. Antal‐Szalmás | P. Antal-Szalmas
[1] K. Farkas,et al. Sa1156 Accelerated Treatment Strategy in Inflammatory Bowel Diseases; Is It Associated With a Change in the Disease Course? , 2015 .
[2] L. Kupčinskas,et al. Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe. , 2015, World journal of gastroenterology.
[3] M. Papp,et al. Serological studies in inflammatory bowel disease: how important are they? , 2014, Current opinion in gastroenterology.
[4] G. Veres,et al. Incidence rates and disease course of paediatric inflammatory bowel diseases in Western Hungary between 1977 and 2011. , 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[5] P. Lakatos,et al. Inflammatory bowel disease course in Crohn's disease: is the natural history changing? , 2014, World journal of gastroenterology.
[6] M. Vatn,et al. Risk Matrix for Prediction of Advanced Disease in a Population-based Study of Patients with Crohn's Disease (the IBSEN Study) , 2014, Inflammatory bowel diseases.
[7] M. Sans,et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. , 2013, Gastroenterology.
[8] J. Mary,et al. Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. , 2013, Gastroenterology.
[9] L. Peyrin-Biroulet,et al. Moving towards disease modification in inflammatory bowel disease therapy , 2013, Current opinion in gastroenterology.
[10] N. Pedersen,et al. East–West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort , 2013, Gut.
[11] J. Fell,et al. Disease Phenotype at Diagnosis in Pediatric Crohn's Disease: 5-year Analyses of the EUROKIDS Registry , 2013, Inflammatory bowel diseases.
[12] H. El‐Serag,et al. Natural History of Pediatric-onset Inflammatory Bowel Disease: A Systematic Review , 2012, Journal of clinical gastroenterology.
[13] Zhaoxia Zhang,et al. Anti-Saccharomyces cerevisiae Antibodies Associate with Phenotypes and Higher Risk for Surgery in Crohn’s Disease: A Meta-Analysis , 2012, Digestive Diseases and Sciences.
[14] G. Veres,et al. Has There Been a Change in the Natural History of Crohn's Disease? Surgical Rates and Medical Management in a Population-Based Inception Cohort from Western Hungary Between 1977–2009 , 2012, The American Journal of Gastroenterology.
[15] P. Rosenstiel,et al. Characterization of Changes in Serum Anti-Glycan Antibodies in Crohn's Disease – a Longitudinal Analysis , 2011, PloS one.
[16] Geraint T. Williams,et al. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986–2003): a study of changes in medical treatment and surgical resection rates , 2010, Gut.
[17] J. Girardet,et al. Natural history of Crohn's disease: Comparison between childhood‐ and adult‐onset disease , 2010, Inflammatory bowel diseases.
[18] P. Rutgeerts,et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.
[19] L. Peyrin-Biroulet,et al. The Natural History of Adult Crohn's Disease in Population-Based Cohorts , 2010, The American Journal of Gastroenterology.
[20] P. Lakatos,et al. Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's disease. , 2009, World journal of gastroenterology.
[21] S. Targan,et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[22] J. Belaiche,et al. Predictors of severe Crohn's disease , 2008, Scandinavian journal of gastroenterology.
[23] G. Veres,et al. Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients , 2007, Inflammatory bowel diseases.
[24] Laurent Beaugerie,et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. , 2006, Journal of Crohn's & colitis.
[25] P. Seksik,et al. Predictors of Crohn's disease. , 2006, Gastroenterology.
[26] J. Satsangi,et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[27] S. Greenland,et al. Simulation study of confounder-selection strategies. , 1993, American journal of epidemiology.
[28] M. Picco. Perianal Disease Predicts Changes in Crohn's Disease Phenotype—Results of a Population-Based Study of Inflammatory Bowel Disease Phenotype , 2009 .
[29] J. Lennard-jones,et al. Classification of inflammatory bowel disease. , 1989, Scandinavian journal of gastroenterology. Supplement.